| Trial ID: | L2488 |
| Source ID: | NCT00044460
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
Efficacy and Safety In Poorly Controlled Type 2 Diabetics
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: rosiglitazone
|
| Outcome Measures: |
Primary: Change in HbA1c from baseline to Week 24. | Secondary: Change in FPG (fasting plasma glucose) from baseline to Week 24; characterize the effects of rosiglitazone on the albumin-creatinine ratio at Week 24.
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
142
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2002-05
|
| Completion Date: |
2003-04-10
|
| Results First Posted: |
|
| Last Update Posted: |
2017-10-09
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00044460
|
